Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection

Major clinical trials using prostate-specific antigen (PSA) as the screening test to detect localized early-stage prostate cancer and to attempt to change its natural history with early intervention have yielded conflicting interpretations. The US Prostate, Lung, Colorectal, and Ovarian (US PLCO) ca...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JNCI : Journal of the National Cancer Institute 2013-10, Vol.105 (20), p.1534-1539
Hauptverfasser:	Haines, Ian E, Gabor Miklos, George L
Format:	Artikel
Sprache:	eng
Schlagworte:	Androgen Antagonists - adverse effects Androgen Antagonists - therapeutic use Antineoplastic Agents, Hormonal - adverse effects Antineoplastic Agents, Hormonal - therapeutic use Biomarkers, Tumor - blood Clinical Trials as Topic Early Detection of Cancer Europe - epidemiology Evidence-Based Medicine Humans Male Mass Screening Neoplasm Staging Predictive Value of Tests Prostate-Specific Antigen - blood Prostatectomy Prostatic Neoplasms - diagnosis Prostatic Neoplasms - drug therapy Prostatic Neoplasms - immunology Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Prostatic Neoplasms - surgery Radiotherapy, Adjuvant Selection Bias United States - epidemiology Watchful Waiting - statistics & numerical data
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!